Standout Papers

Revised Recommendations of the International Working Group for Diagnosis, ... 1997 2026 2006 2016 1.8k
  1. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003)
    Bruce D. Cheson, John M. Bennett et al. Journal of Clinical Oncology
  2. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study (2000)
    Marilyn L. Slovak, Kenneth J. Kopecky et al. Blood
  3. Age and acute myeloid leukemia (2006)
    Frederick R. Appelbaum, Holly Gundacker et al. Blood
  4. All-trans-Retinoic Acid in Acute Promyelocytic Leukemia (1997)
    Martin S. Tallman, Janet W. Andersen et al. New England Journal of Medicine
  5. Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study (1997)
    Catherine P. Leith, Kenneth J. Kopecky et al. Blood
  6. Langerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative Disease (1994)
    Cheryl L. Willman, Lambert Busque et al. New England Journal of Medicine
  7. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. (1990)
    Kevin E. Noonan, Christian Beck et al. Proceedings of the National Academy of Sciences
  8. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study (2008)
    Michael J. Borowitz, Meenakshi Devidas et al. Blood
  9. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia (2013)
    Stephen H. Petersdorf, Kenneth J. Kopecky et al. Blood

Immediate Impact

12 by Nobel laureates 20 from Science/Nature 79 standout
Sub-graph 1 of 19

Citing Papers

Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
2023 Standout

Works of Cheryl L. Willman being referenced

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)
2014
Delivery of Small Interfering RNA by Peptide-Targeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers
2012

Author Peers

Author Last Decade Papers Cites
Cheryl L. Willman 12064 6302 8286 232 20.0k
Daniel J. DeAngelo 8805 4208 6062 438 15.9k
Hervé Dombret 13182 5915 7064 369 18.4k
Alan K. Burnett 18802 6546 10036 347 23.1k
Charles G. Mullighan 8045 9442 5686 295 18.4k
Dieter Hoelzer 7148 5176 4532 321 16.1k
Mel Greaves 4854 5732 5367 163 13.2k
Sergio Amadori 9706 2913 4055 359 15.2k
Dario Campana 8890 8505 5050 285 22.0k
Oliver G. Ottmann 10174 3196 4850 369 15.8k
Deborah A. Thomas 12009 5599 6207 448 22.7k

All Works

Loading papers...

Rankless by CCL
2026